Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ruxolitinib cream in children with nonsegmental vitiligo
NL-OMON60047Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib in nonsegmental vitiligo and Vitiligo, sponsored by Incyte. Primary endpoint: Proportion achieving F-VASI75 at Week 24. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
nonsegmental vitiligoVitiligo
Beyond the preview
Go deeper on NL-OMON60047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60047.